Thirty-one intensively pretreated children with ALL in first bone marrow relapse or refractory to initial therapy were treated with a combination of intermediate-dose Ara-C and idarubicin (IDA). Twenty-four patients (77%) achieved complete remission (CR), 8 patients relapsed early and 2 were removed from the study. Fourteen (45% of the original 31 patients) underwent bone marrow transplant (BMT) and 7 of them (22%) are still in continuous CR (CCR) with a median follow-up of 18 months. These results confirm that it is possible to achieve CR even in ALL children who failed on an initial intensive regimen. Newer modalities of post-remission therapy, especially for children lacking an HLA donor, should be considered.
Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children / Testi, A.M., Moleti, M.l., Giona, F., Iori, A.p., Meloni, G., Miniero, R., Pigna, M., Amadori, S., Mandelli, F.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 3:(1992), pp. 765-767.
Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children.
TESTI, Anna Maria;Giona F;MELONI, Giovanna;MANDELLI, Franco
1992
Abstract
Thirty-one intensively pretreated children with ALL in first bone marrow relapse or refractory to initial therapy were treated with a combination of intermediate-dose Ara-C and idarubicin (IDA). Twenty-four patients (77%) achieved complete remission (CR), 8 patients relapsed early and 2 were removed from the study. Fourteen (45% of the original 31 patients) underwent bone marrow transplant (BMT) and 7 of them (22%) are still in continuous CR (CCR) with a median follow-up of 18 months. These results confirm that it is possible to achieve CR even in ALL children who failed on an initial intensive regimen. Newer modalities of post-remission therapy, especially for children lacking an HLA donor, should be considered.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
